- Thinly traded nano cap Celsion (CLSN +129.8%) is up on a whopping 36x surge in volume in response to its announcement of final results from a Phase 1b dose-escalating study of DNA immunotherapy GEN-1 in patients with advanced Stage III/IV ovarian cancer. The data were presented yesterday evening at the American Association of Cancer Research Special Conference in Pittsburgh, PA.
- Of the 14 patients who completed the study, two were complete responders, 10 were partial responders and two had stable disease, implying a 100% disease control rate and an 86% objective response rate.
- GEN-1 is an interleukin 12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, a technology platform the company calls TheraPlas. It is designed to stimulate the local production and secretion of IL-12, a potent inducer of anti-cancer immunity, around the tumor site.
- Previously: Celsion completes OVATION study and provides update on advanced stage III and IV Ovarian Cancer; shares ahead 34% premarket (July 5)
- Now read: OncoMed Pharmaceuticals: Is This .50 Busted IPO A Buy?
Original article